Peter DeMuth

Hoofd Techniek/Wetenschap/O&O bij ELICIO THERAPEUTICS, INC.

Vermogen: - $ op 30-04-2024

38 jaar

Health Technology

Finance

Consumer Services

Actieve functies van Peter DeMuth

Bedrijven	Functie	Begin	Einde
ELICIO THERAPEUTICS, INC.	Hoofd Techniek/Wetenschap/O&O	01-01-2022	-

Bedrijven	Functie	Begin	Einde
Elicio Therapeutics, Inc. (Old) Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA.	Hoofd Techniek/Wetenschap/O&O	01-08-2017	01-06-2023

Massachusetts Institute of Technology	Doctorate Degree
University of Maryland	Undergraduate Degree

Internationaal

Verenigde Staten

Operationeel

Sectoraal

Beklede functies

Actief

Inactief

Beursgenoteerde bedrijven

Bedrijven in privébezit

Beursgenoteerde bedrijven	1
ELICIO THERAPEUTICS, INC.	Health Technology

Bedrijven in privébezit	1
Elicio Therapeutics, Inc. (Old) Elicio Therapeutics, Inc. (Old) BiotechnologyHealth Technology Elicio Therapeutics, Inc. engages in the development of vaccines for infectious disease and cancer. Its programs focus on a novel lipid nanocapsule platform technology for delivering vaccines in a form mimicking the structure of pathogens to elicit potent immunity in prophylactic and therapeutic settings. The company was founded by Satish Jindal and Darrell Irvine on August 10, 2011 and is headquartered in Cambridge, MA.	Health Technology

Bedrijven in privébezit

Health Technology